• 1
    Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26: 153-161.
  • 2
    Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
  • 3
    Wong VW, Wong GL, Chim AM, Choi PC, Chan AW, Tsang SW, et al. Surrogate endpoints and long-term outcome in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2009; 7: 1113-1120.
  • 4
    Sung JJ, Tsoi KK, Li KC, Wong VW, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepato-cellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077.
  • 5
    Hui AY, Chan HL, Cheung A, Cooksley G, Sung JJ. Treatment of chronic hepatitis B virus infection by pegylated interferon: systematic review of 4 randomized studies. Aliment Pharmacol Ther 2005; 22: 519-528.
  • 6
    Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drug 2009; 69: 2167-2177.
  • 7
    Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-308.
  • 8
    Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-1897.
  • 9
    Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758.
  • 10
    Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468.
  • 11
    Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Piegnoux M, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
  • 12
    Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
  • 13
    Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, et al. Genotype C hepatitis B virus infection is associated with increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498.
  • 14
    Chan HL, Wong GL, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Alanine aminotransferase based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36-44.
  • 15
    Sung JJ, Chan HL, Wong ML, Tse CH, Yuen SC, Tam JS, et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat 2002; 9: 229-234.
  • 16
    Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004; 115: 217-222.
  • 17
    Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 182-187.
  • 18
    Chan HL, Tsang SW, Liew CT, Tse CH, Wong ML, Ching JY, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97: 406-412.
    Direct Link:
  • 19
    Chan HL, Wong GL, Wong VW. A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir Ther 2009; 14: 489-499.
  • 20
    Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133: 843-852.
  • 21
    Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82.
  • 22
    Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B. Clin Gastroenterol Hepatol 2009; 7: 227-233.
  • 23
    Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. Am J Gastroenterol 2008; 103: 3071-3081.
    Direct Link:
  • 24
    Chan HLY, Leung NWY, Hui AY, Wong VWS, Liew CT, Chim AML, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon alfa-2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-250.
  • 25
    Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis B with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745-754.
  • 26
    Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12: 345-353.
  • 27
    Chan HL, Wong VW, Chim AM, Choi PC, Chan HY, Hui AY, et al. Virological response to different combination regimes of peginterferon alfa-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther 2007; 12: 815-823.
  • 28
    Chan HL. Antiviral therapy for chronic hepatitis B: the challenges of Hong Kong. J Hepatol 2009; 51: 1088-1090.